A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non‑small Cell Lung Cancer (NSCLC) (ROSETTA Lung‑201)

Trial status:Recruiting
Trial ID:
CA266-0001
NCT ID:
NCT07361497
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Bristol-Myers Squibb
Collaborator:
BioNTech SE
Recruiting

Trial Details

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Medical Condition
  • Lung Cancer
    • Study Drug
  • Pumitamig
    • See more
  • Durvalumab
    • Phase
    Phase 3
    Type
    Interventional
    Estimated Enrolment
    850
    Estimated Trial Date
    Mar 2026 - Sep 2030

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No
    Inclusion and Exclusion Criteria
    Inclusion criteria

      Inclusion Criteria

    • Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
    • Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
    • Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
    • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

      • Exclusion Criteria

    • Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
    • Participants must not have an active autoimmune disease.
    • Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
    • Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or current or suspected ILD or pneumonitis.
    • Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
    • Other protocol-defined Inclusion/Exclusion criteria apply.

    Trial Locations

    Location
    Status
    Location
    Southern Cancer Center Pc
    Daphne, Alabama, United States, 36526
    Status
    Recruiting
    Location
    Local Institution - 0780
    Chandler, Arizona, United States, 85224
    Status
    Not yet recruiting
    Location
    Local Institution - 0585
    Golden, Colorado, United States, 80401
    Status
    Not yet recruiting
    Location
    Medical Oncology Hematology Consultants, PA
    Newark, Delaware, United States, 19713
    Status
    Recruiting
    Location
    Local Institution - 0711
    Ocala, Florida, United States, 34474
    Status
    Not yet recruiting
    Location
    Local Institution - 0756
    Marietta, Georgia, United States, 30060
    Status
    Not yet recruiting
    Go to page